Higher-dose radiation shows promise in canine AGASACA

A newly published study in the Journal of Small Animal Practice reports that a dose-escalated radiation protocol of 10 × 4.0 Gy was associated with substantially better long-term locoregional control in dogs with apocrine gland anal sac adenocarcinoma than a comparison protocol of 8 × 3.8 Gy. In the retrospective cohort, dogs treated with the higher-dose regimen also had longer median overall survival and progression-free survival, with adverse effects that investigators said remained clinically manageable. (lifescience.net)

That finding lands in a disease setting where treatment decisions are often multimodal, and where the role of radiation continues to evolve. A 2025 review of radiotherapy in canine AGASACA said surgery remains the primary treatment for most dogs, but also emphasized that evidence is still limited on how best to prescribe radiation across definitive, adjuvant, and palliative settings. The review specifically called for more work on how total dose and fraction size affect outcomes and complications, underscoring that fractionation is still very much an open clinical question. (link.springer.com)

In the new study, investigators evaluated dogs treated with three-dimensional conformal radiation therapy between September 2016 and September 2025. Dogs receiving chemotherapy agents other than toceranib phosphate were excluded, helping narrow treatment heterogeneity somewhat, though the study remained retrospective. Group A received 10 fractions of 4.0 Gy and included 15 dogs, while Group B received 8 fractions of 3.8 Gy and included 11 dogs. Median overall survival was 1,534 days in Group A versus 821 days in Group B. Median progression-free survival was 926 days versus 258 days, and median local progression-free survival was 1,554 days versus 351 days. At the 3-month CT follow-up, response rates were 90.9% in the higher-dose group and 10.0% in the comparison group. The 1-year local progression-free survival rate was 93.3% in Group A and 45.5% in Group B. (lifescience.net)

The toxicity signal will likely get close attention from clinicians, because pelvic radiation for AGASACA can raise understandable concern about late gastrointestinal and perianal effects. Here, the authors reported that all observed radiation-related adverse effects were clinically manageable. That aligns directionally with earlier retrospective work using image-guided IMRT for anal sac adenocarcinoma, where investigators found acute toxicity was common but generally resolved or improved within weeks, and late toxicities such as chronic colitis, ulceration, stricture, or myelopathy were not observed in that cohort. Still, the treatment platforms differed, and cross-study comparisons should be made cautiously. (lifescience.net)

Industry and academic commentary has been moving toward the same broader point: radiation can be useful in AGASACA, but protocol selection matters. The 2025 review concluded that even so-called palliative hypofractionated protocols may deliver meaningful disease control in some dogs, while also noting that current practice patterns vary and that evidence is not yet strong enough to settle on one standard approach. The authors of that review said further investigation is warranted to define the optimal prescription and better understand patterns of failure after both radiation and surgery. (link.springer.com)

Why it matters: For veterinary professionals, this study may be most relevant in referral oncology settings where teams are weighing how aggressively to pursue locoregional control in dogs with AGASACA. The apparent gains in local progression-free survival are notable, because pelvic disease control can shape quality of life, downstream intervention needs, and case selection for surgery, systemic therapy, or both. At the same time, the paper doesn't settle every practical question. It was a small retrospective cohort, used a specific three-dimensional conformal protocol, and compared two regimens within a single study population rather than against surgery alone or a standardized multimodal pathway. That means the findings are promising, but not yet practice-defining on their own. (lifescience.net)

The study also fits into a broader trend in canine oncology toward more tailored radiation planning. Earlier literature has explored conformal planning for AGASACA, and more recent work has examined definitive-intent IMRT and SBRT approaches for selected cases, especially when surgery is declined or nodal disease is difficult to resect. Taken together, the field appears to be moving away from a one-size-fits-all view of hypofractionation and toward matching dose, fractionation, and technology to disease burden and treatment goals. That is an inference based on the recent review and the cited retrospective studies, rather than a formal consensus statement. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next step is whether prospective or multicenter retrospective studies validate the 10 × 4.0 Gy regimen, clarify which dogs benefit most, and define how it compares with surgery-first or multimodal strategies in real-world referral practice. (lifescience.net)